<SEC-DOCUMENT>0001628280-23-034316.txt : 20231013
<SEC-HEADER>0001628280-23-034316.hdr.sgml : 20231013
<ACCEPTANCE-DATETIME>20231013091116
ACCESSION NUMBER:		0001628280-23-034316
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20231013
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231013
DATE AS OF CHANGE:		20231013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		231324023

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cpix-20231013.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:c86a165f-e85c-4abe-81ea-6fbaf38133c3,g:13940c62-0aa2-4c74-ac53-916de1682fb4,d:322109973a9f40b780a83a3d70523dc0--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20231013</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20231013.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-13</xbrli:startDate><xbrli:endDate>2023-10-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i322109973a9f40b780a83a3d70523dc0_1"></div><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">October 13, 2023 (<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">October 13, 2023</ix:nonNumeric>)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.059%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Tennessee</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33637</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2525 West End Avenue, Suite 950</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">37203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">615</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">255-0068</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:33.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i322109973a9f40b780a83a3d70523dc0_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01 &#160;&#160;&#160;&#160;Other Events</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2023, Cumberland Pharmaceuticals Inc. announced a new publication in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antimicrobial Agents and Chemotherapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> detailing the results of the first reported clinical study investigating the safety and pharmacokinetics of Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> injection in children 2 to 17 years of age. This publication describes results of an open-label study aimed at characterizing a single 10 mg/kg dose of Vibativ in children 2 to 17 years of age who required systemic antibiotics for the treatment of a known or suspected bacterial infection. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vibativ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is an intravenous antibiotic approved by the FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) as well as complicated skin and skin structure infections (cSSSIs) caused by certain gram-positive bacteria in adults.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the release is furnished as </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="vibativpedspublication.htm">Exhibit 99.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.461%"><tr><td style="width:1.0%"></td><td style="width:18.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vibativpedspublication.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="vibativpedspublication.htm">Press release dated October 10, 2023</a></span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i322109973a9f40b780a83a3d70523dc0_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:16.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated:  October 13, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vibativpedspublication.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib604bc70ce8b484aa44b7cc81145398d_1"></div><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:88px;margin-bottom:5pt;vertical-align:text-bottom;width:388px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">NEW VIBATIV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%"> PEDIATRIC PUBLICATION </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">HIGHLIGHTS ITS SAFETY </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">IN PATIENTS 2 TO 17 YEARS OF AGE</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">NASHVILLE, Tenn. (October 10, 2023) &#8211; Cumberland Pharmaceuticals Inc. (NASDAQ&#58; CPIX) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">announced today a new publication in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">Antimicrobial Agents and Chemotherapy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> detailing the results of the first clinical study investigating the safety and pharmacokinetics of Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">telavancin)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> injection in children 2 to 17 years of age. Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">is an intravenous antibiotic approved by the FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP&#47;VABP) as well as complicated skin and skin structure infections (cSSSIs) caused by certain gram-positive bacteria in adults</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. This is the first reported study evaluating Vibativ in pediatric patients. </font></div><div style="margin-bottom:8pt;padding-left:0.7pt;text-align:justify;text-indent:-0.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8220;Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a problem for children. New, effective and safe therapy, particularly once-daily therapy, will be welcomed by those who care for children with serious MRSA infections requiring intravenous therapy,&#8221; said first author Dr. John Bradley, Distinguished Professor of Pediatrics, University of California San Diego School of Medicine and Medical Director of Infectious Disease at Rady Children&#8217;s Hospital of San Diego.  </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">This publication describes results of an open-label study aimed at characterizing a single 10 mg&#47;kg dose of Vibativ in children 2 to 17 years of age who required systemic antibiotics for the treatment of a known or suspected bacterial infection. Of the 22 patients treated in the study, 14 were 12 to 17 years of age, 7 were 6 to 11 years of age and one was 2 years of age. The study found a single 10 mg&#47;kg dose of Vibativ was safe with no serious adverse events or renal concerns. Drug exposure to Vibativ was lower in children compared with observations in adult patients</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="height:40.01pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">&#8220;Antimicrobial resistance poses a significant challenge in the treatment of bacterial infections, necessitating the development of new antibiotic therapies. The results of this study suggest that a single dose of Vibativ is safe in children and they experience reduced exposure to Vibativ, compared with the same body weight-based dosing in adults,&#8221; said corresponding author Dr. Antonio Arrieta, Professor of Pediatrics, University of California Irvine and Medical Director of Pediatric Infectious Disease, Children&#8217;s Hospital of Orange County.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">For full prescribing and important safety information, please see the brand&#8217;s website at </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">www.vibativ.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">. </font></div><div style="margin-bottom:8pt;padding-left:28.4pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">1. Bradley JS, Goldman JL, James, LP, Kaelin B, Gibson BHY, Arrieta A. Pharmacokinetics and Safety of a Single Dose of Telavancin in Pediatric Subjects Aged 2 to 17 Years of Age. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">Antimicrob Agents Chemother. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">October 10, 2023. </font></div><div style="margin-bottom:8pt;padding-left:28.4pt;text-align:justify;text-indent:-14.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">2. Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:174%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> (telavancin) &#91;Package Insert&#93;. Cumberland Pharmaceuticals Inc. Nashville, TN&#59; 2020.</font></div><div style="margin-bottom:12pt;padding-left:28.8pt;text-align:justify;text-indent:-14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">3. Worboys PD, Wong SL, Barriere SL. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:174%">Eur J Clin Pharmacol.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%"> 2015 Jun 1&#59;71(6)&#58;707&#8211;14. </font></div><div style="margin-bottom:6pt;padding-left:14.4pt;text-align:justify;text-indent:-14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">About Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:174%;position:relative;text-decoration:underline;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline"> (telavancin) for Injection</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information please visit </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">www.vibativ.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:40.01pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">About Cumberland Pharmaceuticals</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. The company develops, acquires, and commercializes brands for the hospital acute care, gastroenterology and rheumatology market segments. The company&#8217;s portfolio of FDA-approved brands includes&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-25.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%;padding-left:21.2pt">Acetadote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:133%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:133%">acetylcysteine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">) injection, for the treatment of acetaminophen poisoning&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-25.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%;padding-left:21.2pt">Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:133%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:133%">ibuprofen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">) injection, for the treatment of pain and fever&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-25.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%;padding-left:21.2pt">Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:133%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:133%">lactulose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">) for oral solution, a prescription laxative, for the treatment of constipation&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-25.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.2pt">Omeclamox</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">-Pak</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">omeprazole, clarithromycin, amoxicillin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) for the treatment of Helicobacter pylori (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">H. pylori</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) infection and related duodenal ulcer disease&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-25.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.2pt">Sancuso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">granisetron) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-25.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.2pt">Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">conivaptan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-25.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21.2pt">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">telavancin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy (&#8220;DMD&#8221;) and Systemic Sclerosis (&#8220;SSc&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">For more information on Cumberland&#8217;s approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the company&#8217;s website </font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">www.cumberlandpharma.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%;text-decoration:underline">.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%;text-decoration:underline">Forward-looking Statements&#58; </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland&#8217;s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the company&#8217;s intent, belief or expectations, and can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;seek,&#8221; &#8220;anticipate&#8221; and other comparable terms or the negative thereof. As with any business, all phases of Cumberland&#8217;s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland&#8217;s operation results. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland&#8217;s products on a timely basis, failure of </font></div><div style="height:40.01pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the company&#8217;s control as more fully discussed in its most recent 10-Q as filed with the SEC. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:174%">SOURCE&#58; Cumberland Pharmaceuticals Inc.</font></div><div style="padding-left:99pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.076%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Investor Contact&#58;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Media Contact&#58;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Shayla Simpson</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Molly Aggas</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Cumberland Pharmaceuticals Inc.</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Dalton Agency</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(615) 255-0068</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(704) 641-6641</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:40.01pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cpix-20231013.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c86a165f-e85c-4abe-81ea-6fbaf38133c3,g:13940c62-0aa2-4c74-ac53-916de1682fb4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://cumberlandpharma.com/20231013" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cumberlandpharma.com/20231013">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20231013_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20231013_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cpix-20231013_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c86a165f-e85c-4abe-81ea-6fbaf38133c3,g:13940c62-0aa2-4c74-ac53-916de1682fb4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_SecurityExchangeName_3668aa06-9b3a-47ca-8da1-87235ef17387_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f5d425a3-df71-4082-bcd5-c125e5b8bf67_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_6538bb98-34ca-44ed-9751-3b0273448019_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ffe40e8c-8d8b-48bd-8274-e31f83dfa67e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_179deeae-915b-4c89-bc24-b957e3fe47f0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9b09e4d4-7435-4981-ba90-be4706edb52f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3bddbd79-3fe1-43a2-8554-eee42538d1a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_ac0a5b85-a229-499f-afc7-ffb9a6a54869_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5f508711-e37c-4238-a0e5-66be06e40576_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_2aa2404f-e1be-46a3-93e3-841565442266_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ddae60b3-0c0e-4a46-9529-d7d19fb77b7d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_56c7acb2-15cf-4a7b-aff8-c73d8b4d4a38_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_eb446071-1636-4622-97e5-be0567998dcd_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b631067d-0829-4008-937c-eb3900575415_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8ce35710-9c52-4ae7-b40e-9b1d25202a94_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d94dcb1a-07ee-4027-875e-1ef534cfedf3_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e18ff667-f936-45a4-af6c-de6c5b8c58e9_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e49471f7-ac3d-4f66-95a6-799b29f93408_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_681f165e-61d3-4a87-a7cd-88e3c8a2a594_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d7eee594-7a0a-4d63-a638-1e391617692b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f789dee4-348f-4061-9824-87be6610fd77_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b0b93ff0-fbd9-479c-ba66-9e5bd6f3afe2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4f6c9b8f-f2a5-4bc9-bb31-64d9b2b7b6af_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cpix-20231013_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c86a165f-e85c-4abe-81ea-6fbaf38133c3,g:13940c62-0aa2-4c74-ac53-916de1682fb4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="cpix-20231013.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5f4f0477-bed0-4379-b0a6-4003a697c4e5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_DocumentType_5f4f0477-bed0-4379-b0a6-4003a697c4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4085acaf-e69c-4cd3-9c98-288899f9954e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_DocumentPeriodEndDate_4085acaf-e69c-4cd3-9c98-288899f9954e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cdcfac72-d74f-4cc5-9ae9-9b7a6dea27a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_EntityRegistrantName_cdcfac72-d74f-4cc5-9ae9-9b7a6dea27a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7005a839-1ce8-4bfc-9fa3-5b27b57dad08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_EntityCentralIndexKey_7005a839-1ce8-4bfc-9fa3-5b27b57dad08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_262dc7cd-03f9-4107-86e6-b7c5baa6f7ae" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_AmendmentFlag_262dc7cd-03f9-4107-86e6-b7c5baa6f7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3b9051cc-0dcf-44c0-baca-29858b601da6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3b9051cc-0dcf-44c0-baca-29858b601da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_88b6988d-31b8-4078-b9c6-3e9e14624519" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_EntityFileNumber_88b6988d-31b8-4078-b9c6-3e9e14624519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_3b879f87-a1fa-4c88-8269-57c471b34f0a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_EntityTaxIdentificationNumber_3b879f87-a1fa-4c88-8269-57c471b34f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_65c68ca1-fb8d-4ee8-8a9c-8591dfbf9e30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_CityAreaCode_65c68ca1-fb8d-4ee8-8a9c-8591dfbf9e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a1615890-e684-4b3d-9373-d463ec3b1cea" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_LocalPhoneNumber_a1615890-e684-4b3d-9373-d463ec3b1cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_b4437c09-6fee-452b-a4fd-abdcfafb7b20" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_WrittenCommunications_b4437c09-6fee-452b-a4fd-abdcfafb7b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_6d595b2c-744d-437f-b1ee-01da7dd1f0b1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_SolicitingMaterial_6d595b2c-744d-437f-b1ee-01da7dd1f0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c8155409-852e-45a1-a177-58a5b8d60ba8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_PreCommencementTenderOffer_c8155409-852e-45a1-a177-58a5b8d60ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_c19609fd-092f-46d6-90bb-b4b3564f1df8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_c19609fd-092f-46d6-90bb-b4b3564f1df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_42d432b2-f9a8-4bd1-ae58-87575850fb6a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_Security12bTitle_42d432b2-f9a8-4bd1-ae58-87575850fb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b5060f8a-1456-4206-aa20-da46cb60b44f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_TradingSymbol_b5060f8a-1456-4206-aa20-da46cb60b44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7c6c15b0-3451-4225-8480-df1c7618d009" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_SecurityExchangeName_7c6c15b0-3451-4225-8480-df1c7618d009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c8f71bca-56d9-4e12-94e7-088d64369fc2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_EntityEmergingGrowthCompany_c8f71bca-56d9-4e12-94e7-088d64369fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_86bb93ca-479e-4e65-9478-55cd321fa7da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_EntityAddressAddressLine1_86bb93ca-479e-4e65-9478-55cd321fa7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d35a224e-3698-4a59-8279-72ae535f6cbb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_EntityAddressPostalZipCode_d35a224e-3698-4a59-8279-72ae535f6cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_a2e9caad-3294-4d8b-ab68-00a7311c45fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_EntityAddressCityOrTown_a2e9caad-3294-4d8b-ab68-00a7311c45fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_9aa6ea71-eaff-4f65-96ef-13f8bfc90b95" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f016288e-ea21-4e1f-8f2d-0b2e82a06893" xlink:to="loc_dei_EntityAddressStateOrProvince_9aa6ea71-eaff-4f65-96ef-13f8bfc90b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !8 80# 2(  A$! Q$!_\0
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M445\:>F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT1]<T445Y1UA1Z^W%?AA_P %Q_VV_'/[/GP5\%?L\_L\:GJ,/[4_[5'BS2?
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MT]4]S]9:3('4@?C7P+_P2W\:^+OB-_P3]_97\;^//$.K>+/%_B7X4Z%JFO\
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MV:4 @]#GM7YH_$C]L"/XJ_L6?"3]HGX$>))_#/A3XX:S\.+"_P#'3VUI-?\
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MJGB:W\.:)J6L7=]X?\&6_B76DCU;Q!;^$M)FMM$AUB_C2XO4M!(PVE:^9_\
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M@^/7QAUS1OCR?AI8_L5NFD?LR+9ZCK5GIGQ)_::T:ZM]8\>^+M673(6MM?\
M!OAC^SC\';*SNA/976IWWC>Y3=Y-I*G[<?LD?M&^&OVJO@)X"^,OAP+;3>(=
M*2'Q-HC96Z\-^+].Q9^)= NX7/FPRZ?JD4\<0F DDMC;S$#S *VQF3XC!86A
MBJCE)5.6-:G[.45AZE2G&I2AS/2:E3EJTDHS4HZN+9-'%0JU)TU9)7<6I7YX
MIVEI96L_-IJS3/I,G R?\_Y_SSQ6;!K.D7-Y+I]OJFG3W\ S/90WMM)=P@YP
M9;9)3-&#@@;T&3P*_.?_ (*->,?%-C:_LS_"BS\8:W\-OAY\>OV@= ^&OQ<^
M('AO4IM"UO2_!5SHVL:J?#^F^);=XI_#-QXUU33[+PR^M02PW4%OJ$T5E<6]
MY-!,OIY_X)^?L6Z3:^&]0TSX,^$_!NI^#M5TKQ!HWCOPIJ>M>"_'-MJ.EWMM
M>075Y\1/#^KZ7XMU$7L\$::M'JFN7<&MPR36VJ1W<-Q)&_/'"4(X:C7KU:L?
MK"JJE&A251)4VX\U24JM-7E.ZY%S223D])*[=63J3ITU%JE;FYY<NLN5VBDG
M=).U]%MN]%]M8YS_ (?X9]^#UY]:K27UE"[1S7=K%(N"R23Q(XSR"59@W(Y'
M%61C P01@<@Y'Y]Z_ K6OA9I_P 5?^"A/[;\>N?LE>$_VH8- M_@-!IUQXO\
M7^%-"7P:+WX<0S3VFF6OB@OO34I%^U7#V2I'YB#SLO@U67X&.,6)<ZKHPPN'
MC7;7LDYWKT:*BG6JT81NZJ?O3N[<JBVU=UZSI*G:/,ZDE'[5E[KF_AC-_9MH
MM?)'[XQ3PW">9!*DJ$E0\;!UR.HW+D9'>E>6*,H))$C:5MD8=@I=@"VU >68
M*"VU03@$XP#7C'[/G@71OAW\+="\.:)\(M"^!D"S:C>W/PU\.W^DZIIFB7MS
M>2K)+'J&B8TVZ?4(8H+V1[?A#,(G_>1N3\L?MLZHVD_'G_@FG/+?R:?I]W^V
M-KVE7TIN'M[6X?4OV6/VB+72["[.Y8I1>:L]E#:6\N1-??9EC4S",5E1PGM\
M5]6ISDDO:.,K1DY*G!S2:A.47S*-O=E-*][NVKE5Y**J-6TA=:JW-*,;:I/2
M_5(_0YY8HR@DD1&D.V,,R@N<9VJ"<L<<X&3UXXIY8*"Q/ &2?:OS>_;<U*:'
M]H'_ ()TV%I?2PR7_P"TUJAN;.WG=&O+"V^''B-YS/#$X$UI$YC:3S$:-&*E
MB&Q7Z/30QSQ2P3(KPS1O%+&PRKQR*4=&'=64E2/0FLZN']C1PM2_^\TZE2UG
M>"A5J4=W:[;A?I\5EU94:BE*I"UG3E%7OO>"G;3M>SU>Q5_M/3LD&^LQ];J#
M/XC?P<],\\<@5:BEAGC66"2.6-LA9(F5T;:2" RD@[6!!Y.#D<8K\/?VBOV,
M?V6-._;@_8M\*Z?\"OAY9^'/B /CE=^-]$M]"@BTWQ3<Z7X;TN_TZ?6[1<17
M\ME>W$]S;-.K&*:5W7EB:_9'X>?#CP-\)O".E^ OAOX7TCP9X-T7[8=)\-Z#
M:1V.DZ?_ &A?7.IWOV6UCQ'%]JO[RYNY<##S3R.>36^,PF&H4<+4HUJU2>(I
M>UY*E.,(PCSSIM<T:M1N7-3;:27NM:W=E%&I4J2J1G&,53GR74G)MVB[VY8I
M*SVNW?RL=D9(PZQ%U$CAF5"0&95^\0O4@9&2.E.SU_'IU..OZ\5^=?Q6N[M/
M^"EG[*EDEU<)9S_ #X\S36BS2+;2S1:MX0$<LL"L(Y)(P6".ZL4#-MZFOO\
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M/UV[\/WVHV-I>RZ?-+<^&?$6E>*=)=;J']Z@@U?1K&9U4XE1&B;Y7:LOQQ\
M_AU\0/B'\-_BMK>G7=M\0/A7<:A)X3\3:-?SZ7J*66K6_P!FU/0]4DMMO]JZ
M!?+MEN-*O/,MFN(HKA525 P]IHHC7KPC&,*U2,(>TY8J3Y5[51C55MOWD8QC
M+NHJ][('",GK&+[W6NCNON=VNS>F[$(RI7U7'Z8KY.UG]B?]GOQ%\%OB%\ /
M$'@XZS\,OB;XQUWQ[XKT34;^YN);GQ/XBUR'Q%J>HV=Z2MS8.VIPI+;BU=#!
M&7A1O+=@?K*BE2K5Z#?L:U2E><*C<)-/GIN].2MLX._*^EQRA"?Q1C+1QU5]
M&M5K??K\NQXG<_L_?#*X\:?!?QXFA_8]<^ &B^*?#_PQ2PG>TTW0=)\8^'['
MPQKEH=/A M[F.71].M+:V$@ M3%OBY)KUG6=,CUK2=3TB:>[M8=4L+O3YKFP
MG:UOH(KRWDMI)K.Z0%[:ZC24O;W" M#*J2+RHK3HI.K5ER.=24Y4U:#;ORKG
ME4:5[VO.4IO5WE*3W8*$8II124M[==%'7T227D>4?!KX*?#GX"_#/PK\)?AK
MH$.C^#?!]C+9:5:3.;V\F>[O+K4]2U'4K^X#7.H:KJVJ7U[J>J:A<,UQ>W]W
M<7,S&25JI?#'X$?#SX/^(?B5XA\ Z==:++\5_%3>-?%VFI?32:+)XFEM(;.[
MU/3-+;_1M+EU!+>.6_6T"1W5R&N)%\UF8^R44Y5Z\O:<U:I)5FG5C*3DIM/F
MO)/=WN[[KIHK"5."Y;1BN16C96MTTMT=MMCS[XG_  L\ ?&7P;JO@#XE^&-,
M\6^$]92-;W2=4B+Q&6"19K:[MY8V2XL[ZSG1+BSO;26&ZM9T26"5'4&OEY/V
M!/A%-!I6D:]XT^.7B[P;HU]:7]EX \4_%OQ-J?@XO87$5U8V]Y81R6M[J%E:
M300O%:WNHSQ-Y2+,LBY!^XJ*NEB<31A[.G7G&"=U!/W8R:2<HIWLW97:L_,4
MJ4)RYI13DNO5K3?NK]'_ )#418U"*,*HP![#I7QIXV_89^$7C;XI>-?C%_PD
M?Q;\'>-OB%'H$/BZY\ ?$C6O"EAK*^&--32-&>YL+%3"9+2P00"08+#<Q^]7
MV;144JU:BZCI5)4W47+/E;]^'-&3C)/1IRBGZI/=#G3A-)3BI<KNKK5/;1]-
M--.C:>AYO\*_AEI7PE\*Q^$M'U[QAXCLX[Z[OQJ7CGQ'>>*M=,EX(@\#ZM?!
M9VM8O*4V]N1MA+/MSNXR/C;\"_AO^T)X*/@/XG:++JNCPZOI?B/2+RQOKK2M
M=\-^)M#N/M6B^)O#6M6,D-_HNNZ5/NDLM0LYHY(P\L3AX998W]?HI1JU85%5
MC4E&K&7,JD7RR4NZ:M;MITT&X1<>1I.-K6>J:[.^Y\F?#[]C3X4^!/B%H_Q4
MOM7^(OQ*\>>&M,NM(\*:_P#%3QMJ7C.;PG97L:PWO_".VUTEO9:=<WL"+!<W
MRVSWLD(,9N I;=]9T44ZM:K7DI5JDJC2M'F^S'5VBE9)7;;LE=MMZL(PC!6C
M%)7OIWVO]VGH>4^*_@SX&\:?$GX;?%?7;&YN/&7PG3Q)'X,O8[R:&WL5\664
M&GZU]HM$_=7GGVUO$L?F_P"I92R<L:]6HHJ92G+E4I.2A'E@GKRQOS<J[+F<
MG;:\F-)*]DE=W?F[)7?G9)?(\MUGX.^!]?\ BQX.^-.I6%S+X]\!^&O$?A/P
MWJ"7DT=M;:+XJGL;C68)K)?W,\D\NG6ICF?YH@A"_>->I=L=C112<I-14I-J
M,5&*_E6KLK]+MOU;O<$DF^G,[MVZV2OYZ)'R!XB_8E^#^I^,=?\ 'GA+4_B+
M\(O$7BV>2\\6R_"+QOJ?@K3_ !-J$R[)M3UC1[9;G29M4F3Y9M0@L[>ZG^]-
M+(_SCV#X,_ [P'\"?#VH^'_ T&LR?VYK-SXC\2:WXEU_5?$WB/Q)X@NX8+>X
MU?6=8U:XN)[B[>WMK>W585M[6&""*&"WCC0"O7Z*UGB,14CR5*TYPM%.,G>Z
MBDH<SWERI67,W;Y$QIPB[QBD^_Z]E?K:U^IXYX^^!/P]^)GC[X5_$;QGIUUK
M&N_!K4]:USP':S7TW]B:;KNNZ6^C7.MW&CX-I?:K:Z=+<6VF7ERK2:<MU</;
M;))"]3?&;X&_#GX]>!;WX>?$71?[0\/W=_I6K1M8S-INIZ=JVAW\&IZ1JNE:
MG:A;G3]0L+ZVAN+>Z@82(RD<JQ!]=HI1KXB'LN6M->Q25&TG:FKN3Y5>RO)M
MNV]]0=.#YKQC[_Q.VKZ*[W=EI_P-"K96JV-G:6222RI:6T%JDMQ(99Y5@B6)
M9)Y3@RS.$#2R$ NY9B 37QGXI_8/^#_B7XE?$+XL6WB?XP^#?%WQ2OM%U+QN
M_@/XFZWX7TS6K[P]HEKX=TFZFTRR1H$FM=)LH+=63EL,S?,QQ]K44J56M1E.
M5*K*FZBM/E^TN92L_*ZOZV[!*G":BIQ4N757OH^ZUO\ B<QX,\*VG@CPMH?A
M.PU'6]6L]!T^#3K;4?$>IS:SKEW% NU9M3U2X GOKMQS+<2C>YY->"_$[]D[
MP)\3?'$WQ%D\7?%GP-XKO=%B\/ZM>_#KXC:[X7MM8TFW>1H+?4-+C>ZTQI(/
M.E$=U;VEM=8<AIFPN/J&BG"O5IS=2G-QF]Y*VJ;N[K9WMU6^H.$6E%KW5ZIK
MT>_>^MSRSX-_!GX>_ ;P-8_#WX9Z&NA^';.[U#4I5>XN+[4=4UC6+N74-8UO
M6=3NY);S5-8U:_FEO-0U"[DDFN9Y&8L%"J/4Z**B<YU)RG4E*<Y.\I2;<FWU
M;922BE&*225DELD%%%%2,**** "BBB@ KR;X??"#PO\ #WQ?\7/'&E6EN/$G
MQD\967B_Q9J2P*EU=3:3X6T'PAH]G)/S));Z=I&@6RPH6\M9I[J1$5IGW%%7
M&<X1J1C)QC548U$G9349<T5+NE))@XQD[M)N.L=-GHK^MNIZS1114#Z-^:_&
M_P#D%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139820197315328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Oct. 13, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 13,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 West End Avenue, Suite 950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>cpix-20231013_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20231013.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2023-10-13</startDate>
            <endDate>2023-10-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001087294</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2023-10-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33637</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2525 West End Avenue, Suite 950</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">255-0068</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MK6H%.\!O=,H"/G!@!&NN-MP9_OB#UW%_0?B:!5\34R\S.?],>14<'MZ[_(Y
MM J(UGD04ZZ$M!4-"8R+2AY<J2A?7?W:!5H;%=P/KA>^$K:"P#AA<248KC-Z
M?;J]?WGT)W=D^LU_>?)']Z_S\<A_G)'Q9'2%D'8*TLXYI"/(HV(13(>0?Y#O
M_+.*%5=R7==S>UUZW4*PN@56%Q7SH;!A7MR'B*VJ8/#X)8LT1SAZ!4?OG/2,
MDT"J5*K<)R[(S, P(U*1D<P@;Y ^&596%Q>?3Q#"ZX+P^AS"!Q%Q,LGB!5=5
M(+@&5.ZRV>PTNPB/YY8NZYY#-&<?9!Q""<52!#N#/<U7(]FAEUZWTV[2:XSP
M:!WP\&EE^7Q8V$\6KD:@X[4QD-+F/=2EAX\R@$DW7<L$*UZ-"&VW+Z$OZ6%$
MI;%[N#6_*6$,3R Q<9PE^\+I2BI<J&X&>J7->[@[SV0D F%$LB)/,.^48%$E
M#ZY2RU-ZNX>;\E3QRP#2PY. [Q9!\"I8KI^7RQ/UP_5JR4HO]W +_A_96.L,
MR&H!<=E:P-+5/=R6Y\* 3<DE\>A/BY_)C <9C+?*Q:9&R8Y/<)29D<'[!4DD
M29DB&Q9E*&AI^UZ--2L6V@$W^XP7LGJXX0*CZ?@/C*2T=P_WYD..R/U'L&;)
MBI]L)6J$)O[LSO\-:TY+AZ=G.?Q]S-7*9NE74#!KZQDI2RJK62-8-\)H:>T4
M=^8]FA^&T/7JB\,!>83GR'-2F;@:2=JF;?+&M<D[3'_#DXQ##Y )Z &NVRZ&
M?=3OXQ[^%7LJM8&5X4^1GERB:A2;7>JB6Y%R2:"XDW]ERU=/:'[F<IM4@N%R
M$Z;7&Q%%:+W+Q8'BMOX5KFC-IDIN!/A@)2&N6=V7-8XVGG83_\3LX-<DXDM0
M<:^ZX/)JMR_>G1B9YGO1A32PL\T/UYR!$=L'X/Y22G,XL=O;XK\3PW\!4$L#
M!!0    ( &=)35>?H!OPL0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;
M,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L)VEU9=V'L<VA
MR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;
M)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/
M3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O
M_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_
M/LG>V)+;.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)8Q1\V .7\@%:
M^*VZBMU7)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VML*01C\9][/QN]*!_
M[XSC]Y97HA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!
M6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<
M'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72
M[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'
M')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^
M6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]
M?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1
M/,<0F,7XC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\E
MTWLJ.?]74_P$4$L#!!0    ( &=)35>7BKL<P    !,"   +    7W)E;',O
M+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +
M&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P
M6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,
M-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4
M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 9TE-5QPX9>H_ 0  / (   \
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 9TE-5R19,B'M    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 9TE-
M5YE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !G24U7*)=4KV,$  "I$   &
M@($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 9TE-
M5Y^@&_"Q @  X@P   T              ( !I0P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !G24U7EXJ[',     3 @  "P              @ &!#P
M7W)E;',O+G)E;'-02P$"% ,4    " !G24U7'#AEZC\!   \ @  #P
M        @ %J$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 9TE-5R0>
MFZ*M    ^ $  !H              ( !UA$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 9TE-5V60>9(9 0  SP,  !,
M     ( !NQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&!10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cpix-20231013.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cpix-20231013.htm">cpix-20231013.htm</File>
    <File>cpix-20231013.xsd</File>
    <File>cpix-20231013_lab.xml</File>
    <File>cpix-20231013_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cpix-20231013.htm": {
   "nsprefix": "cpix",
   "nsuri": "http://cumberlandpharma.com/20231013",
   "dts": {
    "inline": {
     "local": [
      "cpix-20231013.htm"
     ]
    },
    "schema": {
     "local": [
      "cpix-20231013.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20231013_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20231013_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231013.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20231013.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001628280-23-034316-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-034316-xbrl.zip
M4$L#!!0    ( &=)35>1'GR8WP\   AT   1    8W!I>"TR,#(S,3 Q,RYH
M=&WM75MWVS82?N^OP*IGM\XY)L6+[K:U1U645-O$]EK.IF=?]D D)*&F2!8
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M>C=B:F+SK#8GW(<NBHM]Z/'O!TWGP*.$J2>%ED9*K:)%4IN])XJ?V1/UY?.
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MU/*$++;K;FEK6*_;J%YT-2QSI[26.Q>>B/I@L-CNL?:BCK9?&I?*:.AH4Z*
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M.X(5]\Q*2_78H +8Y^6@L 7*:4P]%O7EUM :2C$A25I[1,8JQQC'TWWJ63"
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M8/;A1)J+^C\V5/\;8O/_4$L#!!0    ( &=)35?F*!W(AP(  -T'   1
M8W!I>"TR,#(S,3 Q,RYX<V3-5<ENVS 0O?LK6)U+:W-<6X@=H$D#!'#3(DW0
MW J*&EE$)%(EJ5CY^Y*T&=O9&@,]5!=1,^_-RAD=G_1-C>Y!*B;X+(B'48"
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M>MW!2%ZFY=1,DECC*!8(Z(1"@$,6 :ET#!2,8A-+)A/2&=Q5\&.#MA85Y$D
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M@=F:K1>0S4B#@=B:P#J [0-\N_$/,U-<I=G5KT5^5U[;N_6-R!XF6@M#0HE
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M]MD,>U_V1]K[L6/"\\S1H!V-(F\63[#$'>[3R<'#B?:C?>?^Y.#_4$L#!!0
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M,RYH=&U02P$"% ,4    " !G24U7YB@=R(<"  #=!P  $0
M@ $.$   8W!I>"TR,#(S,3 Q,RYX<V102P$"% ,4    " !G24U79TV'\G(*
M  !+7@  %0              @ '$$@  8W!I>"TR,#(S,3 Q,U]L86(N>&UL
M4$L! A0#%     @ 9TE-5PDG+,#!!@  0S$  !4              ( !:1T
M &-P:7@M,C R,S$P,3-?<')E+GAM;%!+ 0(4 Q0    ( &=)35>88"JW@A$
M #=L   :              "  5TD  !V:6)A=&EV<&5D<W!U8FQI8V%T:6]N
:+FAT;5!+!08     !0 % $P!   7-@     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
